More Indian imports for Philippines

9 January 2001

The Philippines has imported another consignment of medicine from India,reports the Asia Pulse news service, quoting government officials as saying that the imports cost 20 million pesos ($386,200) but would have cost 100 million pesos if bought locally. The first shipment from India, last July, had cost 1.5 million pesos but would have cost 5 million pesos if purchased in the Philippines (Marketletter June 5, 2000).

The announcement follows the dismissal by a Regional Trial Court of a petition by the Pharmaceutical and Healthcare Association of the Philippines seeking to stop the imports. The judge ruled that the Association, which represents 73 mainly multinational drug companies, failed to prove that imports would lead to "injustice" and "irreparable harm" to the public and drug companies. The petition had also claimed that imports would lead to proliferation of substandard drugs and damage the companies' reputations.

However, the judge's order concluded that "the importation of similarly-branded medicines will be beneficial to patients of government hospitals by making these drugs available to them at a price lower than the prevailing price."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight